No Data
No Data
Earnings Preview: KNSA to Report Financial Results Pre-market on April 29
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $370,475, According to a Recent SEC Filing
Wedbush Maintains Kiniksa Pharmaceuticals International(KNSA.US) With Buy Rating, Maintains Target Price $34
Express News | Wedbush Reiterates Outperform on Kiniksa Pharmaceuticals, Maintains $34 Price Target
Evercore ISI Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)